S5043Referred to Committee

A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-07-21
Introduced
0
Cosponsors
S
Type

Sponsor

Ted Budd
Ted Budd
Republican · NC · Senator
Votes with party: 74.6% (842 recorded votes)

Full profile: /officials/B001305

Source: Congress.gov · FEC

Cosponsors (0)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

No cosponsors on record. Bills can pass without cosponsors — this often means the sponsor introduced the bill alone, either because it's a messaging bill, a chairman's mark, or simply early in the legislative cycle.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

2026-07-21

Source: Congress.gov

Committee Activity

Plain-English Summary

The FDA would be required to strengthen inspections and safety checks on medicines imported from China and other countries to block fake, contaminated, or unapproved drugs from entering the U.S. market. This would protect patients and consumers by ensuring imported medications meet American safety standards before reaching pharmacies and hospitals. The bill also sets up new procedures to identify and stop dangerous or counterfeit drugs at the border.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Full bill text is not yet cached locally.